Article
Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2015
Sinicrope Frank A, Mahoney Michelle R, Yoon Harry H, Smyrk Thomas C, Thibodeau Stephen N, Goldberg Richard M, Nelson Garth D, Sargent Daniel J, Alberts Steven R
Abstract excerpt
PURPOSE: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. EXPERIMENTAL DESIGN: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAF(V600E) and KRAS (exon 2) mutations and DNA mismatch repair (MMR) proteins were analyzed in tumors (N = 3,018) in relationship to tumor location, including subsite. Cox models were used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
